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Objectives. To investigate the relationship between plasma homocysteine and other haemostatic variables and restenoses or
reocclusions after endovascular treatment of symptomatic atherosclerosis of the above-knee femoro-popliteal artery.
Design. Prospective observational study.
Setting. University hospital.
Patients and methods. The study included 103 patients (116 limbs), treated with subintimal angioplasty in 58 cases
(50%) and with intraluminal PTA in 58 (50%): 39 (34%) patients were treated for critical limb ischaemia. Blood samples for
analyses of fasting plasma values of homocysteine, fibrinogen, D-dimer, activated protein C resistance were drawn upon
admission. Median follow-up for all procedures was 11 months (range 0–42 months). Outcome events (arterial patency)
were defined as $50% restenosis or reocclusion in the treated arterial segment. Patency rates were estimated with the
product limit method and Kaplan–Meier curves. Variables found to be related significantly to patency were included in
multivariate analysis performed with the Cox proportional hazard model.
Results. The 1-year cumulative primary patency rate for all procedures was 48%. One-year limb salvage rate in cases of
critical ischaemia was 74%. Multivariate analysis demonstrated significant independent associations between patency rates
and plasma D-dimer, diabetes mellitus, the nature of the lesion treated (stenosis vs. occlusion) and antithrombotic therapy
with aspirin after the procedure. Plasma levels of homocysteine, fibrinogen or activated protein C resistance were not
associated with patency rates. Homocysteine levels were higher in patients with critical limb ischaemia than those with
intermittent claudication.
Conclusions. Early restenosis or reocclusion after endovascular intervention of lesions in the above-knee femoro-popliteal
artery was more frequent following treatment of occlusion (versus stenosis), for patients with diabetes, patients with elevated
D-dimer and those without antithrombotic therapy after the procedure. Plasma homocysteine did not appear to influence the
outcome of endovascular intervention.
Introduction
The incidence of restenosis or reocclusion after
endovascular treatment of symptomatic above-knee
femoro-popliteal atherosclerosis is reported to vary
between 30 and 60%.1 – 3 The risk factors for develop-
ment of a restenosis or a reocclusion following
endovascular interventions are largely unknown. The
progression of atherosclerosis has been suggested as
an important contributor to this problem, since the
lesions display histological similarities to those of
atherosclerosis.4,5 Identification of risk factors for
restenosis or reocclusion would be an aid to clinical
decision making and guidance as to which pharma-
cological agents should be evaluated in future clinical
trials for prevention of restenosis and reocclusion.
The level of plasma homocysteine has been demon-
strated to be an independent risk factor for peripheral
vascular and coronary artery atherosclerosis.6 Results
from studies on the relationship between elevated
homocysteine levels and restenosis after coronary or
peripheral vascular interventions remain controver-
sial.7 – 13
Platelet aggregation and thrombosis, observed at
the site of angioplasty in animal models, suggest a
role for the coagulation and fibrinolytic systems in
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restenosis. However, there exists no clear evidence of
the benefit of antithrombotic treatment on restenoses
or reocclusions after endovascular therapy on peri-
pheral arteries.14
Elevated pre-treatment levels of fibrinogen have
been found to be associated with restenosis after
coronary angioplasty. Blood levels of D-dimer have
been found to be correlated to atherosclerotic burden,
but any predictive value with respect to restenosis or
reocclusion has not been demonstrated.15 Activated
protein C resistance has been associated with venous
thromboembolism but recently was found to be
associated with atherosclerosis and restenosis follow-
ing angioplasty.16
The aim of this study was to investigate the
relationship between plasma levels of homocysteine
and other haemostatic and clinical risk factors and
restenosis or reocclusion after endovascular treatment
of symptomatic atherosclerosis in the above-knee
femoro-popliteal artery.
Patients and Methods
From October 1999 to October 2002, 186 patients (205
limbs) were subjected to endovascular treatment of
symptomatic atherosclerosis of the above-knee
femoro-popliteal artery in our institution. Subintimal
angioplasty was performed in 88 cases and percuta-
neous transluminal angioplasty (PTA) in 117. Twenty-
four cases (16 subintimal angioplasties and eight
PTAs) were excluded because the procedure was
deemed technically unsuccessful. The definition of
an unsuccessful procedure was as follows: PTA:
residual stenosis $50%, subintimal angioplasty:
impaired flow through the reconstruction with or
without residual stenosis $50% (as seen on the post-
treatment angiogram). Thirteen cases were lost to
follow-up, three patients who died within 30 days of
the procedure and 26 who did not have the relevant
blood tests performed also were excluded. Eighteen
redo-procedures on cases subjected to more than one
procedure of the same segment of the femoro-popliteal
artery in the same extremity during the study period
were excluded, i.e. the first procedure was included
and subsequent procedures were excluded. Five
endovascular procedures on anastomotic sites of
above-knee femoro-popliteal bypasses were not
included. Thus the study included the treatment of
116 limbs in 103 patients. There were 41 women and 62
men with a mean age of 74 years (range 49–94). Risk
factors are listed in Table 1.
The indication for treatment was intermittent
claudication in 77 cases (66%) and critical ischaemia
in 39 (34%). Critical ischaemia was defined according
to the second European Consensus Document on
chronic critical leg ischaemia.17 The quality of run-off
was defined on basis of the number of patent crural
vessels. It was not possible to retrieve information on
run-off in two cases.
Occlusions longer than 4 cm were treated with
subintimal technique as described by Bolia et al. in 58
cases (50%) and stenoses (55 cases) or occlusions
shorter than 4 cm (three cases) with intraluminal
percutaneous transluminal angioplasty (PTA) as
described by Dotter and Judkins in 58 (50%).18,19 The
mean length of occlusions treated with subintimal
angioplasty was 11.5 cm (range 3–35 cm). The mean
length of lesions treated with PTA was 3.8 cm (range
0.5–20 cm).
Blood for analysis of fasting plasma homocysteine
(Hcy) (normal range 0–15 mmol/l), fibrinogen (Fibr)
(normal range 2–4 g/l), D-dimer (D dim) (normal
range 0.0–0.5 mg/l), activated protein C resistance,
with exception of patients on oral anti-coagulation
(normal value ,2) was drawn upon admission and
analyzed as described earlier.20 – 22 During the pro-
cedure the patient was given 5000 i.u. of heparin
intravenously and if tolerated, then 160 mg aspirin
daily thereafter. If aspirin was not tolerated, no other
platelet-inhibiting medication was prescribed. Thus 32
of 116 cases (28%) did not take aspirin after the
procedure.
Follow-up of patients treated with subintimal
angioplasty was performed at 1, 3, 6, 9, 12 and 18
months, with ankle/arm pressure measurement and
duplex ultrasound examination of the treated arteries.
Follow-up of patients treated with intraluminal PTA
was performed routinely at 1 and 12 months with
ankle arm pressure measurement and clinical evalu-
ation. However, the majority of the patients were
subjected to more frequent follow up: in cases of
critical ischaemia, recurrence of symptoms or because
of atherosclerotic disease in the contralateral leg. A
reduction in ankle-arm index of more than 10%
combined with reoccurrence of symptoms was
Table 1. Risk factors in 103 patients subjected to endovascular
treatment of 116 above-knee femoro-popliteal stenoses or occlu-
sions. COPD denotes obstructive pulmonary disease
Risk factor %
Heart disease 32
Hypertension, medically treated 42
Diabetes mellitus 26
COPD 10
Stroke 16
Smoking 60
Se-creatinine .125 mmol/l 17
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considered to be a sign of a significant restenosis or
reocclusion and the finding confirmed either by
angiography or duplex ultrasonography. At the end
of the study period, all patients with a patent
reconstruction were invited for a further examination
with ankle-pressure measurement and ultrasound
assessment. If symptoms had reappeared in the period
from the last follow up and ultrasonography con-
firmed a restenosis or reocclusion in the treated
segment, an event was registered at the time of
reoccurrence of symptoms. For patients declining the
end of study follow up, data were censored at the
previous follow-up, when the status of patency was
known. Patency was defined as freedom from either
reocclusion or restenosis $50%, both of these criteria
being used as endpoints. Median follow-up time for all
procedures was 11 months (range 0–42 months).
Median follow-up time for event-free procedures
was 18 months (range 0–39 months) and for pro-
cedures with events 4 months (range 0–42 months).
All data were prospectively entered in a vascular
registry run by the department and analysed with
SPSS 10.0.7 for Windows. Statistical significance was
accepted at p , 0:05: Patency rates were estimated
with the product limit method and illustrated as
Kaplan–Meier curves, using the log-rank test for
comparison of patency rates between groups. Vari-
ables found to be significantly correlated to patency
rates were subjected to multivariate analysis per-
formed with Cox proportional hazard model. Com-
parison of continuous variables between two groups
was done with Student’s t-test and more than two
groups was done with one way analysis of variance
(ANOVA). Mann– Whitney test was applied for
comparison of non-parametric data. Restenoses or
reocclusion rates, limb salvage rates and calculation of
haemostatic and clinical factors affecting patency rates
are based on the number of treated legs. Calculations
concerning homocysteine values and haemostatic
values with respect to other risk factors than patency,
limb salvage and amputation were based on number
of patients.
Results
The technical success rate for all procedures was 88,
82% for subintimal angioplasty and 92% for PTA.
Three patients (1.4%) died within 30 days of the
procedure of causes unrelated to the procedures.
Procedure-related complications are listed in Table 2.
The 1-year cumulative primary patency rate for all
procedures included in the study was 48, 65% for PTA
and 31% for subintimal angioplasty. The 1-year limb
salvage rate for limbs suffering critical ischaemia was
74% for all procedures, 78% for limbs treated with PTA
and 63% for those treated with subintimal angioplasty.
Univariate analysis demonstrated significantly
inferior patency in limbs of patients with elevated
plasma levels of D-dimer (.0.5 mg/l) ðp ¼ 0:019Þ (Fig.
1), diabetes mellitus ðp ¼ 0:038Þ (Fig. 2) and of
occlusions as compared to stenoses ðp ¼ 0:026Þ (Fig.
3). Patency was significantly worse in limbs of patients
not treated with aspirin compared to those treated
with aspirin ðp ¼ 0:043Þ (Fig. 4). However, separate
univariate analysis of occlusions and stenoses, respect-
ively, showed that aspirin treatment significantly
improved patency only after re-canalisation of occlu-
sions ðp ¼ 0:027Þ and not after PTA of stenoses ðp ¼
0:184Þ: Multivariate analysis adjusting for the length of
the lesions, run-off, indication, age, gender, risk
factors, smoking, aspirin treatment and the nature of
the lesion (occlusion or stenosis) showed independent
significant association of all four parameters with
patency rates (Table 3). Plasma levels of Hcy, Fibr or
act prot C res were not found to be associated with
patency rates.
Of 103 patients thirty (26%) had plasma Hcy values
above the upper limit of the normal range (0–
15 mmol/l), including 16/39 (41%) patients with
critical ischaemia. The mean plasma concentrations
of Hcy, Fibr and D-dim were significantly higher in
patients with critical ischaemia as compared to
patients with intermittent claudication (p ¼ 0:028;
0.007 and 0.018, respectively). In cases of critical
ischaemia resulting in amputation, the mean plasma
Hcy was significantly higher than in cases of critical
ischaemia resulting in limb salvage ðp ¼ 0:016Þ: There
was no relationship between the length or the nature
of the lesions (occlusions versus stenoses) and either
run-off status or the plasma variables Hcy, Fibr, D-
dimer or act prot C res.
Discussion
The relationship between elevated homocysteine
concentration and atherosclerosis was first observed
by McCully in patients with homocysteinuria, a
metabolic deficiency resulting from an autosomal
recessive disorder, most commonly due to a cystathio-
nine b synthetase deficiency.23 Homozygotes are more
severely affected than heterozygotes and may be
categorised according to responsiveness to sup-
plementation therapy with vitamins B6, B12 or
folate.24 Mild hyper-homocysteinemia can be caused
by deficiency of the aforementioned vitamins, but
the implications of supplement therapy are yet
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unsettled.25 – 28 The correlation between elevated
homocysteine and coronary, cerebrovascular as well
as peripheral vascular atherosclerosis has been effec-
tively demonstrated. The role of homocysteine in
vascular disease, whether as a causative factor or an
indicator, has not been clarified.7,28,29 Cell culture and
animal model experiments have elucidated several
potential mechanisms by which hyper-homocysteine-
mia may stimulate myointimal hyperplasia: inhibiting
endothelial cell proliferation and stimulating vascular
smooth cell growth,30 endothelial cell damage by
generation of free radicals,31 in combination with
destruction of endothelial cell protective mechanisms
such as nitric oxide and glutathione.32,33 Furthermore,
homocysteine has been found to cause a decrease in
compounds potentially inhibiting vascular smooth
muscle proliferation,34 and to create a procoagulant
milieu through modulation of the coagulation and
fibrinolytic pathway.35 – 38 The nitric oxide inhibiting
mechanism of homocysteine has been linked to an
inhibition of endothelium-dependent vasodilatation
found in vivo and in vitro studies.39,40
The association between restenoses or reocclusions
and elevated homocysteine has not been determined,
although results of several studies on cardio-vascular
interventions have suggested an association. Studies
of the effect of hyper-homocysteinemia on the out-
come of peripheral vascular interventions have been
inconclusive. Irvine and Mireskandari found a
significant relationship between hyper-homocystei-
nemia and vein graft stenosis after infrainguinal
bypass grafting whereas Beattie did not, although his
study showed a significant relationship between
elevated homocysteine values and myointimal
hyperplasia in the vein used for grafting.11,12,40
Results from the Dutch BOA Study, including 150
patients with occluded infrainguinal bypass grafts
(synthetic as well as vein grafts) randomly matched
with 220 cases of patent grafts, revealed no signifi-
cant differences between the groups with respect to
Fig. 1. Comparison of patency rates after 116 above-knee femoro-popliteal endovascular procedures in patients with D-dimer
.0.5 mg/l (broken line) and patients with D-dimer #0.5 mg/l (unbroken line).
Table 2. Procedure-related complications to 116 above-knee femoro-popliteal endovascular procedures in 103 patients
Procedure n Complication n Treatment n
Subintimal angioplasty 58 Distal embolisation 4 Aspiration 4
Distalisation of level 1 Bypass surgery 1
PTA 58 Distal embolisation 3 Aspiration 2
Anticoagulation 1
Dissection 1 None 1
Haematoma 2 None 2
Bleeding 1 Operation 1
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homocysteine values.10 Results from studies of
endovascular interventions are also controversial.
Currie et al. reviewed 66 cases and found, using
multiple logistic regression, that hyper-homocystei-
nemia was an independent risk factor for failure of
all forms for peripheral vascular interventions.13
However, Tsakiris et al. could not reproduce this
finding in 81 cases treated with PTA.41
In our study, homocysteine-levels were not associ-
ated with the development restenoses or reocclusions
after endovascular treatment of the above-knee
femoro-popliteal artery. However, patients with
Fig. 2. Cumulative primary patency rates in patients with diabetes mellitus (broken line) compared to patency rates in non-
diabetic patients (unbroken line). The numbers above the curve indicate patients at risk.
Fig. 3. Comparison of patency rates (Log rank) after endovascular treatment of occlusions (broken line) and stenoses
(unbroken line). The numbers above the curve indicate patients at risk.
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critical ischaemia had significantly higher values of
homocysteine than patients with intermittent claudi-
cation. Furthermore, the patients with critical ischae-
mia resulting in amputation had even higher
homocysteine values than patients with critical
ischaemia whose limbs were salvaged. This indicates
a possible correlation between homocysteine levels
and the degree of atherosclerotic disease of the lower
limb. However, there was no association between
homocysteine levels and the status of run-off, quanti-
fied as number of open crural arteries as seen on the
pre-treatment angiogram. Neither was there a corre-
lation between patency rates and run-off. These
observations suggest that the manifestation of vascu-
lar disease in hyper-homocysteinemia might be
localised to the smaller vessels such as in collaterals,
small branching arteries and/or arterioles.
Patients with diabetes had significantly lower
patency rates compared to non-diabetic patients, in
accordance with earlier reports.1,42 This is in contrast
to bypass surgery as a treatment of femoro-popliteal
atherosclerosis, where patients with diabetes do not
have lower graft patency rates.43 Nevertheless, endo-
vascular intervention is generally the preferred treat-
ment for patients with diabetes, probably because of
their increased co-morbidity and operative risk. Our
findings emphasise the need to identify methods to
prevent restenosis and reocclusion after angioplasty in
the diabetic patient as well as the importance of
meticulous patient follow-up, particularly after angio-
plasty for critical ischaemia.
The importance of anti-platelet therapy to prevent
restenoses or reocclusions after PTA in peripheral
arteries has not been settled.14 We found significantly
inferior patency rates in patients not receiving aspirin
therapy after the procedure. When analysing sub-
groups, i.e. stenoses versus occlusions, the beneficial
effect of aspirin was significant only for cases with
occlusions. However, as this was not a randomised
study of the effect of aspirin, this result cannot be
regarded as conclusive.
The significant association between pre-procedural
Table 3. Multivariate analysis (Cox’ proportional hazard model) of risk factors demonstrated with univariate analysis to be significantly
associated with patency rates in 116 above-knee femoro-popliteal endovascular reconstructions
Variables b Standard error 95% CI p-Value Hazard ratio
Occlusion vs. stenosis 0.720 0.269 1.212–3.482 0.007 2.055
Diabetes mellitus 0.905 0.289 1.401–4.358 0.002 2.471
D-dimer .0.5 mg/l 0.564 0.270 1.037–2.983 0.036 1.758
No aspirin 0.597 0.258 1.095–3.011 0.021 1.816
Fig. 4. Comparison of patency rates (Log rank test) in cases treated with aspirin (unbroken line) and not treated with aspirin
(broken line) after 116 above-knee femoro-popliteal endovascular procedures in 103 patients. The numbers above the curve
indicate patients at risk.
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plasma D-dimer concentration and patency following
endovascular therapy of peripheral arteries has not
been reported previously. The implication of our
finding is, that patients who are at increased risk of
restenosis or reocclusion after endovascular therapy,
may be those patients with more extensive athero-
sclerotic disease with concomitant increase in fibrino-
lytic activity. This finding may not be causative, but it
suggests the need to explore the possible benefits of
post-procedural antithrombotic therapy in patients
with altered activity of their coagulation system.
The 1-year patency rate of 48% for the whole group
may appear low for a study including intraluminal
PTA and subintimal angioplasty. The term patency in
our study is defined as a freedom from$50% stenoses
as well as occlusions, in cases that were submitted to a
thorough follow-up. The 1-year primary patency rate
procedures performed with intraluminal PTA was
65%, comparable to a previous report.3 The poor 1-
year patency rates for cases treated with subintimal
recanalisation has been demonstrated in our earlier
studies.1 – 3 Thus the relatively high proportion of
procedures done with subintimal technique (50%) is
reflected in the low overall 1-year patency rate. A
probable explanation for the difference in the patency
rates is the nature of the lesion treated, longer
occlusions demanding subintimal angioplasty whilst
stenoses or short occlusions were treated with PTA.
This explanation is supported by the improved
patency rates following the treatment of stenoses
compared to occlusions in this study.
The aetiology of development of restenoses and
reocclusions after endovascular therapy is probably
multifactorial. Our study indicates that the levels of
homocysteine and activated protein C do not play a
major role. We conclude that the major factors affecting
development of restenoses or reocclusions are related
to the activity of the patient’s fibrinolytic system, the
presence of diabetes mellitus and antithrombotic
therapy after the procedure. However, there seems to
be a relationship between the degree of atherosclerotic
disease of the lower limb and levels of plasma
homocysteine. The need for randomised interven-
tional studies of homocysteine lowering therapy on
restenosis after endovascular treatment of peripheral
arteries with is questionable. We suggest that random-
ised studies on the possible effect of homocysteine-
lowering therapy on peripheral circulation on the
progression to or of critical ischaemia would be more
important. Studies of the effect of peri and post-
procedural anticoagulation or antithrombotic therapy
in patients with diabetes mellitus and/or elevated
fibrinogen and D-dimer also could be considered.
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